Granted by the “Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation”, the awarding of the certificate demonstrates the important R&D activity that takes place in VIVEbiotech, and will allow French clients to obtain important tax deductions on R&D services hired to the company.
In addition to manufacturing clinical quality lentiviral vectors, VIVEbiotech has a research laboratory in which important research activities are carried out to overcome the main barriers that exist today in the gene therapy field: 1) the achievement of more cost-effective processes and 2) the enchancement of the safety profile of lentiviral vectors. VIVEbiotech is working on the improvement of producer cell lines, on new pseudo-typing strategies, and on the development of its own worldwide licensed technology: a non-integrative episomal stable lentiviral vector called LENTISOMA.
For more information about the certification and its processing, go to the Ministry’s website: http://www.enseignementsup-recherche.gouv.fr/pid24835/credit-impot-recherche-cir.html